CROS NT Extend Medidata pact to deploy Medidata’s next-gen EDC and RTSM systems
CROS NT announced an extension of its partnership with Medidata to provide customers with Medidata’s next-gen EDC and RTSM systems.
Under the partnership, CROS NT will offer its customers with RaveX—the latest generation of Medidata’s industry-leading EDC system, Medidata Rave—as well as Medidata’s randomization and trial supply management (RTSM) system, Medidata Balance. The Data Management division in CROS NT offers Sponsors of clinical trials resources that are certified in the use of RaveX and Balance, on a project basis or in the form of functional service provision (FSP).
Services offered by the Data Management team include database build, data management and medical coding, all of which can be delivered from Europe, USA and India. CROS NT has put in place a range of both statistical and data management technologies along with processes to give Sponsors oversight of the quality of monitoring and the quality of data coming from sites.
CROS NT CEO, Andrew MacGarvey said that the extended partnership is part of on-going development in operational capability. CROS NT makes significant efforts to remain at the forefront of innovation. They are always seeking more efficient solutions for customers needing clinical trial services. Therefore, they are pleased to announce the extension of their partnership with Medidata who are making great strides in the development of their own technology platform that allow them to better serve the needs of their expanding client base. This is especially important in the context of recent ICH E6 R2 guidelines, which call for a risk-based approach to clinical trials. He look forward to working with Medidata to deliver effective solutions for their customers.
Medidata’s VP of global partnerships, Rick Bernstein said that they are thrilled to be expanding their relationship with CROS NT, a company that delivers high-quality clinical research services and understands the unique needs of its sponsors – from large pharmaceutical companies to small and mid-size pharma, biotech and medical device developers. CROS NT’s further investment in the Medidata platform exemplifies its dedication to leveraging cutting-edge technology to support today’s most complex, data-driven research programs, and they look forward to further helping them advance their customers’ scientific goals.